文献速递甲状腺核医学核素与放射性配体治疗

BRAF V600E与TERT启动子突变共存预测甲状腺乳头状癌放射性碘治疗疗效不佳

The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-02

研究纳入2016年10月至2019年8月接受放射性碘治疗的126例甲状腺乳头状癌患者,按2015年美国甲状腺协会(ATA)指南标准评估疗效。结果显示BRAF V600E与TERT启动子突变共存组中52.9%(9/17)为放射性碘难治,且该双突变与更低的卓越缓解达到时间相关,多因素分析确认M1、BRAF及TERT突变为放射性碘难治的独立预测因素。

要点

  • 126例中无突变、仅BRAF V600E、仅TERT启动子、双突变分别占15.8%、68.3%、2.4%、13.5%。
  • 双突变组52.9%(9/17)为放射性碘难治,多因素分析确认M1、BRAF、TERT突变为独立预测因素。
  • 双突变组中卓越缓解、不确定缓解、生化不完全缓解分别占35.3%、41.2%、23.5%。

核心结论

  • BRAF V600E与TERT启动子突变共存与甲状腺乳头状癌放射性碘治疗疗效不佳显著相关。

研究设计与样本

  • 研究纳入2016年10月至2019年8月接受放射性碘治疗的126例患者,治疗与随访按2015年ATA指南标准定义,随访结束时评估为卓越缓解或放射性碘难治。
  • 临床试验注册号:ChiCTR1800018760。

主要发现

  • 126例分为无突变、仅BRAF V600E突变、仅TERT启动子突变、双突变共存4组,分别占15.8%、68.3%、2.4%、13.5%。
  • 双突变共存组中52.9%(9/17)为放射性碘难治。
  • 多因素logistic回归分析确认M1、BRAF突变、TERT突变为预测放射性碘难治的独立因素。
  • 双突变组中卓越缓解、不确定缓解、生化不完全缓解分别占35.3%、41.2%、23.5%。
  • Kaplan-Meier分析显示BRAF V600E与TERT启动子突变共存与更低的卓越缓解达到时间相关。

关键数值与推荐

  • 放射性碘治疗反应按2015年ATA指南标准评估为卓越缓解和放射性碘难治。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The BRAF V600E and TERT promoter mutations are well known to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide (RAI)-refractory can be evaluated in advance of treatment, for which predictive biomarkers may be helpful. The present study is to analyze the correlation of both mutations with the curative effect of radioiodine therapy. METHODS: A total of 126 patients who underwent RAI therapy from October 2016 to August 2019 were recruited. Treatment and follow-up were defined according to criteria used in the 2015 ATA guidelines. The RAI response of patients was assessed as excellent response (ER) and RAI-refractory at the end of follow-up. RESULTS: When dividing the 126 patients into 4 groups, the no mutation, only BRAF V600E mutation, only TERT promoter mutation, and coexistence of two mutation groups were found in 15.8%, 68.3%, 2.4%, and 13.5% patients. RAI-refractory was found in 52.9% (9/17) patients with the coexisting BRAF and TERT mutations. In logistic regression analysis, M1, BRAF, and TERT mutation were confirmed to be independent factors predicting the RAI-refractory. Moreover, 35.3%, 41.2%, and 23.5% of patients in the BRAF and TERT mutation group were assessed as ER, SIR, and BIR respectively. Kaplan-Meier analyses revealed that the genetic duet of BRAF V600E and TERT promoter mutations was associated with a lower ER reached time. CONCLUSIONS: We found that BRAF V600E and TERT promoter mutation is significantly correlated with the poor curative effect of RAI therapy in PTC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: ChiCTR1800018760.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cao J, Zhu X, Sun Y, et al. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35501518. doi:10.1007/s00259-022-05820-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。